Journal article
The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder
BJU international, Vol.100(1), pp.107-110
07/2007
DOI: 10.1111/j.1464-410X.2007.06926.x
PMID: 17552957
Abstract
OBJECTIVETo assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).PATIENTS AND METHODSWe conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (> or =8 voids/24 h) and UUI (> or=5 episodes/week) for > or = 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.RESULTSCompared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.CONCLUSIONSThese results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.
Details
- Title: Subtitle
- The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder
- Creators
- Roger Dmochowski - Vanderbilt University Medical CenterKarl Kreder - University of IowaScott MacDiarmid - Atrium Health Wake Forest BaptistMartin Carlsson - PfizerZhonghong Guan - Pfizer
- Resource Type
- Journal article
- Publication Details
- BJU international, Vol.100(1), pp.107-110
- DOI
- 10.1111/j.1464-410X.2007.06926.x
- PMID
- 17552957
- ISSN
- 1464-4096
- eISSN
- 1464-410X
- Language
- English
- Date published
- 07/2007
- Academic Unit
- Obstetrics and Gynecology; Urology
- Record Identifier
- 9984383918502771
Metrics
14 Record Views